Understanding the Heterogeneity and Dysfunction of HDL in Chronic Kidney Disease: Insights from Recent Reviews

Overview

Journal BMC Nephrol

Publisher Biomed Central

Specialty Nephrology

Date 2024 Nov 7

PMID 39511510

Authors

Zhen Xu

Shuo Yang

Liyan Cui

Affiliations

Soon will be listed here.

Abstract

Chronic kidney disease (CKD) is a complex disease that affects the global population's health, with dyslipidemia being one of its major complications. High density lipoprotein (HDL) is regarded as the "hero" in the bloodstream due to its role in reverse cholesterol transport, which lowers cholesterol levels in the blood and prevents atherosclerosis. However, in the complex internal environment of CKD, even this "hero" may struggle to perform its beneficial functions and could potentially become harmful. This article reviews HDL heterogeneity, HDL subclasses, functional changes in HDL during the progression of CKD, and the application of HDL in CKD treatment. This review aims to deepen understanding of lipid metabolism abnormalities in CKD patients and provide a basis for new therapeutic strategies.

Citing Articles

Association of Small HDL Subclasses with Mortality Risk in Chronic Kidney Disease.

Stadler J, Borenich A, Pammer A, Emrich I, Habisch H, Madl T Antioxidants (Basel). 2025; 13(12.

PMID: 39765838 PMC: 11673888. DOI: 10.3390/antiox13121511.

References

Stoekenbroek R, Stroes E, Hovingh G . ApoA-I mimetics. Handb Exp Pharmacol. 2014; 224:631-48. DOI: 10.1007/978-3-319-09665-0_21. View

Kennedy D, Tang W, Fan Y, Wu Y, Mann S, Pepoy M . Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease. J Am Heart Assoc. 2013; 2(2):e000104. PMC: 3647254. DOI: 10.1161/JAHA.112.000104. View

Boucher J, Nguyen T, Sparks D . Lipoprotein electrostatic properties regulate hepatic lipase association and activity. Biochem Cell Biol. 2007; 85(6):696-708. DOI: 10.1139/o07-137. View

Soto-Miranda E, Carreon-Torres E, Lorenzo K, Bazan-Salinas B, Garcia-Sanchez C, Franco M . Shift of high-density lipoprotein size distribution toward large particles in patients with proteinuria. Clin Chim Acta. 2012; 414:241-5. DOI: 10.1016/j.cca.2012.09.028. View

Lucke S, Levkau B . Endothelial functions of sphingosine-1-phosphate. Cell Physiol Biochem. 2010; 26(1):87-96. DOI: 10.1159/000315109. View

Inker L, Astor B, Fox C, Isakova T, Lash J, Peralta C . KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014; 63(5):713-35. DOI: 10.1053/j.ajkd.2014.01.416. View

Homma K, Homma Y, Shiina Y, Wakino S, Suzuki M, Fujishima S . Skew of plasma low- and high-density lipoprotein distributions to less dense subfractions in normotriglyceridemic chronic kidney disease patients on maintenance hemodialysis treatment. Nephron Clin Pract. 2013; 123(1-2):41-5. DOI: 10.1159/000351506. View

Rothblat G, Phillips M . High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol. 2010; 21(3):229-38. PMC: 3215082. DOI: 10.1097/mol.0b013e328338472d. View

Roehm B, Weiner D . Blood pressure targets and kidney and cardiovascular disease: same data but discordant guidelines. Curr Opin Nephrol Hypertens. 2019; 28(3):245-250. PMC: 6673668. DOI: 10.1097/MNH.0000000000000492. View

10.

Rajkovic M, Rumora L, Juretic D, Zanic Grubisic T, Flegar-Mestric Z, Vrkic N . Effect of non-genetic factors on paraoxonase 1 activity in patients undergoing hemodialysis. Clin Biochem. 2010; 43(18):1375-80. DOI: 10.1016/j.clinbiochem.2010.08.024. View

11.

DE LALLA O, GOFMAN J . Ultracentrifugal analysis of serum lipoproteins. Methods Biochem Anal. 1954; 1:459-78. DOI: 10.1002/9780470110171.ch16. View

12.

Zhang L, Yan F, Zhang S, Lei D, Charles M, Cavigiolio G . Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nat Chem Biol. 2012; 8(4):342-9. PMC: 3792710. DOI: 10.1038/nchembio.796. View

13.

Krause B, Remaley A . Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr Opin Lipidol. 2013; 24(6):480-6. DOI: 10.1097/MOL.0000000000000020. View

14.

Pavanello C, Turri M, Strazzella A, Tulissi P, Pizzolitto S, De Maglio G . The HDL mimetic CER-001 remodels plasma lipoproteins and reduces kidney lipid deposits in inherited lecithin:cholesterol acyltransferase deficiency. J Intern Med. 2021; 291(3):364-370. PMC: 9299003. DOI: 10.1111/joim.13404. View

15.

Terasaka N, Yu S, Yvan-Charvet L, Wang N, Mzhavia N, Langlois R . ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest. 2008; 118(11):3701-13. PMC: 2567835. DOI: 10.1172/JCI35470. View

16.

Meier S, Wultsch A, Hollaus M, Ammann M, Pemberger E, Liebscher F . Effect of chronic kidney disease on macrophage cholesterol efflux. Life Sci. 2015; 136:1-6. DOI: 10.1016/j.lfs.2015.06.005. View

17.

Buga G, Frank J, Mottino G, Hakhamian A, Narasimha A, Watson A . D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet. J Lipid Res. 2007; 49(1):192-205. DOI: 10.1194/jlr.M700433-JLR200. View

18.

Mohammed C, Xie Y, Brewster P, Ghosh S, Dube P, Sarsour T . Circulating Lactonase Activity but Not Protein Level of PON-1 Predicts Adverse Outcomes in Subjects with Chronic Kidney Disease. J Clin Med. 2019; 8(7). PMC: 6678354. DOI: 10.3390/jcm8071034. View

19.

Wang K, Zhang Y, Zhao C, Jiang M . SGLT-2 Inhibitors and DPP-4 Inhibitors as Second-Line Drugs in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials. Horm Metab Res. 2018; 50(10):768-777. DOI: 10.1055/a-0733-7919. View

20.

Rader D, Tall A . The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?. Nat Med. 2012; 18(9):1344-6. DOI: 10.1038/nm.2937. View